Avalon Rare Metals

Enlaza Therapeutics Launches with $61 Million Financing to Advance the First Covalent Biologic Therapeutic Platform

Retrieved on: 
Thursday, December 15, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Avalon, Therapy, Therapeutic index, Scale Venture Partners, Protein, Scripps Research, Patient, Lightspeed Venture Partners, Cancer, Toxicity, Avalon Rare Metals, Disease, Saṃsāra, University of California, San Francisco, UCSF, Technology management, University, Safety, Control, Doctor of Philosophy, Half-life, Pharmaceutical industry

Enlaza Therapeutics , the first covalent biologic platform company, today announced its official launch with the closing of $61 million in seed financing.

Key Points: 
  • Enlaza Therapeutics , the first covalent biologic platform company, today announced its official launch with the closing of $61 million in seed financing.
  • Our covalent biologic platform is white-space technology, and we are pioneering an entirely new class of biologic therapeutics with the potential for significantly improved efficacy and safety to address numerous indications and disease areas.
  • Enlaza has built a highly differentiated therapeutic platform which, for the first time, will enable covalent biologics, said Jay Lichter, Ph.D., Managing Partner of Avalon Ventures.
  • The War-Lock platform creates highly specific therapeutic warheads that lock onto targets of interest, producing broadly applicable therapeutic candidates with excellent drug-like properties.

Avalon BioVentures Raises First Fund Dedicated to Early-Stage Biotech Investments

Retrieved on: 
Tuesday, December 6, 2022
Biotechnology, Finance, Health, Professional Services, Pharmaceutical, IPO, Therapy, PDI, Onyx Pharmaceuticals, Infection, Degenerative disease, Ecosystem, R, Accelerator, Life, Drug discovery, CPA, Science, Cancer, Neurodegeneration, Avalon Rare Metals, Research, Investment, Vertex Pharmaceuticals, Translation, GSK, Health, Neurocrine Biosciences, Pharmaceutical industry, Merck, Sanofi

Avalon BioVentures emerged from Avalon Ventures (Avalon) shared life-science/high-tech investing funds as a life-science only fund and will continue to leverage Avalons proven team and company accelerator (the Accelerator) to create, fund, and lead companies developing breakthrough therapies to improve health.

Key Points: 
  • Avalon BioVentures emerged from Avalon Ventures (Avalon) shared life-science/high-tech investing funds as a life-science only fund and will continue to leverage Avalons proven team and company accelerator (the Accelerator) to create, fund, and lead companies developing breakthrough therapies to improve health.
  • Avalon BioVentures builds on nearly four decades of success and experience at Avalon in identifying scientific breakthroughs and translating them into innovative medical products, said Jay Lichter, Ph.D., Managing Partner, Avalon BioVentures.
  • Our investors saw the outstanding value we created in our therapeutics companies through our industry-defining Accelerator and enthusiastically committed capital to ABV1, our first fund dedicated solely to biotech investments.
  • The team at Avalon BioVentures learned the Avalon method over decades of experience as founders and entrepreneurs in Avalon portfolio companies.

Jnana Therapeutics Announces Second Collaboration with Roche to Address Challenging-to-Drug Targets in Cancer, Immune-Mediated and Neurological Diseases

Retrieved on: 
Tuesday, November 15, 2022
Avalon, Avalon Rare Metals, PKU, ROG, Polaris Partners, RO, Regulation, SLC, CSO, Factor X, Partnership, Cancer, Therapy, Multimedia, Patient, SLC6A19, Degenerative disease, CEO, Phenylketonuria, RAPID, Vaccine, Pharmaceutical industry, Jnana

BOSTON, Nov. 15, 2022 /PRNewswire/ -- Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced the company has entered into a second collaboration and license agreement with Roche (SIX:RO, ROG; OTCQX: RHHBY) for the discovery of small molecule drugs for the treatment of cancer, immune-mediated and neurological diseases. The collaboration covers multiple targets from a diverse range of target classes to address diseases with high unmet need.

Key Points: 
  • The collaboration covers multiple targets from a diverse range of target classes to address diseases with high unmet need.
  • Jnana will conduct discovery and preclinical activities against multiple cancer, immune-mediated and neurological disease targets, and Roche will be responsible for development and commercialization of any resulting products.
  • Jnana Therapeutics is a clinical-stage biotechnology company leveraging its next-generation chemoproteomics RAPID platform to discover medicines for highly validated, challenging-to-drug targets to treat diseases with high unmet need.
  • Jnana is focused on developing first- and best-in-class therapies to treat a wide range of diseases, including rare diseases, immune-mediated diseases and cancer.

Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619

Retrieved on: 
Tuesday, October 25, 2022
Avalon, LinkedIn, Immunoglobulin G, U.S. Securities and Exchange Commission, Pembrolizumab, Therapy, Risk, SEC, Oncology, Growth, Acceleration, Private Securities Litigation Reform Act, Ligand, Annual report, Patient, Multiple myeloma, MBA, Twitter, MPH, Security (finance), Partnership, Nasdaq, Cancer, Escape Room, Serum, Immune system, Trial of the century, NKG2D, Avalon Rare Metals, Industry, Exercise, Multiple Myeloma Research Foundation, MICB, MICA, MMRF, CGEM, GLOBE, ADCC, NK, Creativity, COVID-19, Ownership, Pharmaceutical industry, Vaccine, MD

CAMBRIDGE, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology, today announced that it has increased its ownership in its Cullinan MICA, Inc. (MICA) subsidiary from 54% to 92%. MICA holds the worldwide rights to CLN-619, an antibody that restores the MICA/MICB pathway to promote tumor cell lysis from both cytotoxic innate and adaptive immune cells. CLN-619 is being investigated as both monotherapy and in combination with checkpoint inhibitor therapy in an ongoing Phase I study in patients with advanced solid tumors. Cullinan increased its ownership by purchasing equity from two of MICA’s financial investors, Avalon Ventures and Bregua Corporation, for $30.7 million. The Myeloma Investment Fund, a venture philanthropy fund for the Multiple Myeloma Research Foundation (MMRF), maintained its ownership in the entity.

Key Points: 
  • MICA holds the worldwide rights to CLN-619, an antibody that restores the MICA/MICB pathway to promote tumor cell lysis from both cytotoxic innate and adaptive immune cells.
  • Cullinan increased its ownership by purchasing equity from two of MICAs financial investors, Avalon Ventures and Bregua Corporation, for $30.7 million.
  • The Myeloma Investment Fund, a venture philanthropy fund for the Multiple Myeloma Research Foundation (MMRF), maintained its ownership in the entity.
  • Cullinan Oncology has acquired additional ownership in the MICA subsidiary as part of our overall strategy to deploy our robust financial resources for pipeline investment, acceleration, and expansion, said Nadim Ahmed, Chief Executive Officer of Cullinan Oncology.

Biocom California Adds to its Board of Governors

Retrieved on: 
Tuesday, June 28, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, University, Education, Avalon, Bay Area Council, Research, NIH, Organovo, Trauma, Lists of diseases, University of California, San Diego, Cornell University, Stanford University, Avalon Rare Metals, Town School for Boys, Injury, University, Forbes, National academy, Genomics, Association, Infection, MBA, Therapy, Organization, Risk management, Solution, San Francisco Bay Area, Gilead Sciences, Kent State University College of Public Health, LinkedIn, CEO, Biotechnology, Novartis, CRISPR, Inflammation, Public policy, STEM, Biogen, Health, Public health, Takeda, National Academy of Medicine, Drug discovery, CDC, Princeton University, Violence, Epidemiology, Notre Dame, Neurodegeneration, Management, Pharmaceutical industry, Twitter, Science, Facebook

As a member-driven organization, we rely on our board of governors, which consists of highly qualified life science leaders, to ensure that we are meeting the needs of the biotechnology community in California, said Joe Panetta, president and CEO of Biocom California.

Key Points: 
  • As a member-driven organization, we rely on our board of governors, which consists of highly qualified life science leaders, to ensure that we are meeting the needs of the biotechnology community in California, said Joe Panetta, president and CEO of Biocom California.
  • He was recently recognized by the National Diversity Council as a Top 50 California Diverse Leader and was awarded the Leadership Excellence Award by the California Diversity Council.
  • Founded in 1995 in San Diego, Biocom California provides the strongest public voice to research institutions and companies that fuel the local and state-wide economy.
  • For more information on Biocom California, please visit our website at www.biocom.org .

ZTEM AT KIRKHAM PROPERTY IDENTIFIES SIGNIFICANT ANOMALIES EXTENDING FROM NICKEL MOUNTAIN INTO THUNDER NORTH

Retrieved on: 
Thursday, April 28, 2022
FSE, Anomaly, Seabridge Gold, Frankfurt Stock Exchange, Gold, TSX Venture Exchange, Newcrest Mining, MTS, Multimedia, View, Map, Conversation, Stuhini Formation, Director, KSM, Silver, Company, News, Heart, National instrument, Mining, Copper, Brucejack/Bowser Aerodrome, CEO, Vera, Kerr Sulphurets Mitchell, SEDAR, Board of directors, Equilateral triangle, Avalon Rare Metals, Golden Triangle (Massachusetts), Cinder Mountain, Columbia, Nature, Press release, Golden Triangle, National Instrument 43-101, Qualified person (European Union), Nickel, Survey, Oil, Palladium, Surveying, Rare-earth element, Risk management, Property, BC, Eskay Creek

He went on to add, "the results from this ZTEM survey over Thunder North confirm what investors have hypothesized over recent years, and answers the question of whether there are anomalies that cross the property border from Nickel Mountain to the Metallis' Kirkham Property.

Key Points: 
  • He went on to add, "the results from this ZTEM survey over Thunder North confirm what investors have hypothesized over recent years, and answers the question of whether there are anomalies that cross the property border from Nickel Mountain to the Metallis' Kirkham Property.
  • Three new ZTEM-conductivity anomalies on the Property lie along trend from the Nickel Mountain Gabbro that hosts Garibaldi Resources Corp.'s E & L nickel deposit; and
    Garibaldi's "Unexplained" Valley ZTEM anomaly extends up to 700 meters into the Kirkham Property and appears related to another series of geological structures.
  • The third, noted as an "In-Line ZTEM Anomaly", is an additional 900 meters further along trend and lies wholly within the Kirkham Property.
  • The Kirkham Property is contiguous to Garibaldi Resources Corp.'s E&L Nickel Mountain Project in the north and Eskay Mining Corp. to the east.

Digital Healthcare Company, AristaMD, Secures Funding for Integration and Expansion of Care Transition Services

Retrieved on: 
Wednesday, March 30, 2022
Avalon, Health equity, LinkedIn, Avalon Rare Metals, Diagnosis, EConsult, Blue, Growth, Insurance, Health, Patient, Blue Cross, Accountable care organization, Hospital, CEO, Specialization, Communication, Technology, Industry, Acquisition, Twitter, Time, COVID-19, PCP, Solution, Equitable, SAN, Stanford University Medical Center, Acos, Blue Shield, Health insurance, Medicine, Cobalt

SAN DIEGO, March 30, 2022 /PRNewswire-PRWeb/ -- AristaMD, a leading care management company that provides eConsult and referral management solutions, today announced the close of its latest financing to help integrate and expand services that increase patient access and lower healthcare costs. Lead investor Cobalt Ventures joined existing investors including .406 Ventures, Ascension Ventures, Avalon Ventures, Cigna Ventures, CU Healthcare Innovation Fund, MemorialCare Innovation Fund and Stanford Health Care in the financing.

Key Points: 
  • "AristaMD is developing tools that connect primary care providers with specialist advice and care transition services when and where that advice and care is needed.
  • "Responding quickly to a patient's need for specialist care and choosing the appropriate care setting and support services impacts patient outcomes and financial performance.
  • AristaMD's eConsult solution empowers primary care providers to expand their scope and collaborate on patient care with a world-class panel of on-demand specialists.
  • Rapid communication combined with decision-support allows for the selection of the appropriate care setting and healthcare services for each patientaccelerating care, enhancing health equity, improving outcomes and lowering the cost of care."

Metallis Announces Completion of 2021 Drill Program At Kirkham Property

Retrieved on: 
Wednesday, November 3, 2021
Geology, Avalon Rare Metals, Program, Golden Triangle, FSE, KSM, MTS, Property, Symphonia: sum fluxae pretium spei, Company, CEO, Equilateral triangle, Uranium

VANCOUVER, BC, Nov. 3, 2021 /PRNewswire/ -Metallis Resources Inc.(TSXV: MTS) (OTCQB: MTLFF) (FSE: 0CVM) (the "Company" or "Metallis") announcestoday that it has now completed the Company's 2021 drill program (the "Program") at its 100%-owned Kirkham Property (the "Property").

Key Points: 
  • VANCOUVER, BC, Nov. 3, 2021 /PRNewswire/ -Metallis Resources Inc.(TSXV: MTS) (OTCQB: MTLFF) (FSE: 0CVM) (the "Company" or "Metallis") announcestoday that it has now completed the Company's 2021 drill program (the "Program") at its 100%-owned Kirkham Property (the "Property").
  • Fiore Aliperti, Metallis' President and CEO stated, "We are delighted to have completed another successful drill season at the Kirkham Property.
  • Metallis completed 7 long drill holes averaging 684 meters per hole for a total of 4785 metres drilled ( Click Here to View Map of Drill Collar Locations ).
  • The 2021 drill program highlighted broad intercepts of highly silicified and well-mineralized porphyry intrusions and host rocks expanding the Cliff-Miles porphyry corridor both vertically and laterally.

Jnana Therapeutics Closes $50 Million Series B Financing to Advance Lead PKU Program and Small Molecule Pipeline Based on Next Gen Chemoproteomic Platform

Retrieved on: 
Wednesday, August 18, 2021
Biotechnology, Pharmaceutical, Genetics, Health, Avalon, Polaris Partners, SLC6A19, Twitter, Blood, Therapy, PAH, Metabolic disorder, Family, Phenylalanine, SLC, PKU, Biology, RAPID, Patient, LinkedIn, Avalon Rare Metals, Pharmaceutical industry

Jnana Therapeutics , a biotechnology company utilizing its next generation chemoproteomic platform to target SLC transporters and other well-validated but hard-to-drug targets, today announced the closing of a $50 million Series B financing.

Key Points: 
  • Jnana Therapeutics , a biotechnology company utilizing its next generation chemoproteomic platform to target SLC transporters and other well-validated but hard-to-drug targets, today announced the closing of a $50 million Series B financing.
  • Proceeds from this financing will enable Jnana to progress its lead program for the treatment of phenylketonuria (PKU) into clinical development, while advancing a pipeline of additional programs and continuing to invest in its innovative and validated RAPID platform for the discovery of small molecule therapeutics for hard-to-drug targets.
  • We believe that Jnanas lead program offers a differentiated approach to PKU with an oral small molecule, identified using our RAPID platform, that can be used to treat any PKU patient, notwithstanding age or PAH mutation.
  • We are excited about the Jnana teams progress building a pipeline, including their compelling lead program for PKU, and the ability of the companys powerful small-molecule discovery platform to drive continued pipeline growth.

Avalon Completes Non-Brokered Private Placement for Gross Proceeds of $500,000

Retrieved on: 
Friday, May 14, 2021
Chemistry, Physical sciences, Chemical elements, Natural sciences, Alkali metals, Reducing agents, Biomaterials, Tantalum, Lithium, Forward-looking statement, Caesium, Avalon Rare Metals

A similar work program involving geochemical surveys and detailed geological mapping and sampling is planned for the Lilypad property with a focus on identifying additional cesium occurrences.

Key Points: 
  • A similar work program involving geochemical surveys and detailed geological mapping and sampling is planned for the Lilypad property with a focus on identifying additional cesium occurrences.
  • The Company now has four advanced stage projects, providing investors with exposure to lithium, tin and indium, as well as rare earth elements, tantalum, cesium and zirconium.
  • Forward-looking statements include, but are not limited to statements related to how the Company plans to use the net proceeds from the Private Placement and that proceeds from this offering will be used primarily to continue to advance the Company\'s Lilypad Cesium-Tantalum Project and Separation Rapids Lithium Project.
  • Forward-looking statements are based on assumptions management believes to be reasonable at the time such statements are made.